Peptide Regulatory Landscape
The peptide regulatory landscape shifted significantly in early 2026. Following HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement, approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list are being returned to Category 1, restoring legal compounding access through licensed pharmacies with a physician's prescription. The FDA continues to refine its approach to compounded peptides under the FD&C Act, and state boards of pharmacy and medicine continue to issue their own guidance. Providers must stay current on federal rules, the 503A/503B framework, and state-specific restrictions to maintain compliant practices.
Last updated: April 8, 2026
Active Regulatory Alerts
HHS Reclassifies 14 Peptides From Category 2 Back to Category 1
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be moved back to Category 1. Affected peptides include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. Licensed 503A compounding pharmacies may once again prepare these peptides pursuant to a valid physician prescription. Reclassification does NOT mean the peptides are FDA-approved drugs — the 503A framework, documentation, and medical-necessity requirements still apply.
Source: HHS / FDA
FDA Clarifies Compounded GLP-1 Policy and 'Essentially a Copy' Standard
On April 1, 2026, the FDA issued clarifying guidance reminding 503A pharmacies and 503B outsourcing facilities that compounded drugs qualify for the FD&C Act statutory exemptions only when applicable conditions are satisfied — with specific focus on the 'essentially a copy' standard. Because the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounders preparing GLP-1 analogues must document clinical-difference justification for each patient and should review their 'essentially a copy' analysis.
Source: FDA.gov
GLP-1 Shortages Resolved — Wind-Down Period Enforcement
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Compounding under shortage provisions has ended, and phased enforcement grace periods have expired. 503A pharmacies may continue patient-specific compounding only where a documented clinical difference justifies it (not as an essential copy of the commercial product). Providers should verify each prescription meets the 'essentially a copy' standard.
Source: FDA Drug Shortage Database
DEA Scheduling Considerations for Peptide Practices
While most therapeutic peptides are not scheduled substances, providers should be aware that certain peptide hormones (e.g., synthetic growth hormone analogues) may trigger DEA scrutiny depending on intended use. Maintain thorough documentation of medical necessity for all peptide prescriptions.
Source: DEA Diversion Control
Join 1,000+ Members in Our Community
Connect with patients, health enthusiasts, and providers discussing peptide therapy, regulatory updates, and the latest research.
Join the CommunityLegal Disclaimer
This page is for educational and informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements change frequently. Providers should consult with qualified legal counsel and verify current regulations with the FDA, their state board of medicine, and state board of pharmacy before making compliance decisions.